These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 28536852)

  • 1. The Role of SGLT-2 Inhibitors as Part of Optimal Medical Therapy in Improving Cardiovascular Outcomes in Patients with Diabetes and Coronary Artery Disease.
    Mosleh W; Sharma A; Sidhu MS; Page B; Sharma UC; Farkouh ME
    Cardiovasc Drugs Ther; 2017 Jun; 31(3):311-318. PubMed ID: 28536852
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications.
    Heerspink HJ; Perkins BA; Fitchett DH; Husain M; Cherney DZ
    Circulation; 2016 Sep; 134(10):752-72. PubMed ID: 27470878
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of EMPA-REG OUTCOME
    Naing S; Poliyedath A; Khandelwal S; Sigala T
    Postgrad Med; 2016 Nov; 128(8):822-827. PubMed ID: 27701934
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The potential role of sodium glucose co-transporter 2 inhibitors in the early treatment of type 2 diabetes mellitus.
    Brunton SA
    Int J Clin Pract; 2015 Oct; 69(10):1071-87. PubMed ID: 26147213
    [TBL] [Abstract][Full Text] [Related]  

  • 5. EMPA-REG OUTCOME: The Endocrinologist's Point of View.
    Perreault L
    Am J Med; 2017 Jun; 130(6S):S51-S56. PubMed ID: 28526185
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacologic Management of Type 2 Diabetes Mellitus: Available Therapies.
    Thrasher J
    Am J Med; 2017 Jun; 130(6S):S4-S17. PubMed ID: 28526182
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Update on SGLT2 Inhibitors-New Data Released at the American Diabetes Association.
    Lee S
    Crit Pathw Cardiol; 2017 Sep; 16(3):93-95. PubMed ID: 28742644
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mechanisms linking empagliflozin to cardiovascular and renal protection.
    Perrone-Filardi P; Avogaro A; Bonora E; Colivicchi F; Fioretto P; Maggioni AP; Sesti G; Ferrannini E
    Int J Cardiol; 2017 Aug; 241():450-456. PubMed ID: 28395981
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Meta-Analysis of Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Cardiovascular Outcomes and All-Cause Mortality Among Patients With Type 2 Diabetes Mellitus.
    Tang H; Fang Z; Wang T; Cui W; Zhai S; Song Y
    Am J Cardiol; 2016 Dec; 118(11):1774-1780. PubMed ID: 27666177
    [TBL] [Abstract][Full Text] [Related]  

  • 10. EMPA-REG OUTCOME: The Cardiologist's Point of View.
    Pham SV; Chilton R
    Am J Med; 2017 Jun; 130(6S):S57-S62. PubMed ID: 28526181
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of reducing blood pressure on renal outcomes in patients with type 2 diabetes: Focus on SGLT2 inhibitors and EMPA-REG OUTCOME.
    Scheen AJ; Delanaye P
    Diabetes Metab; 2017 Apr; 43(2):99-109. PubMed ID: 28153377
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Which is the main molecular target responsible for the cardiovascular benefits in the EMPA-REG OUTCOME trial? A journey through the kidney, the heart and other interesting places.
    Luconi M; Raimondi L; Di Franco A; Mannucci E
    Nutr Metab Cardiovasc Dis; 2016 Dec; 26(12):1071-1078. PubMed ID: 27776917
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Revitalization of pioglitazone: the optimum agent to be combined with a sodium-glucose co-transporter-2 inhibitor.
    DeFronzo RA; Chilton R; Norton L; Clarke G; Ryder RE; Abdul-Ghani M
    Diabetes Obes Metab; 2016 May; 18(5):454-62. PubMed ID: 26919068
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SGLT-2 Inhibitors and Cardiovascular Risk in Diabetes Mellitus: A Comprehensive and Critical Review of the Literature.
    Imprialos K; Faselis C; Boutari C; Stavropoulos K; Athyros V; Karagiannis A; Doumas M
    Curr Pharm Des; 2017; 23(10):1510-1521. PubMed ID: 28120716
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardiovascular benefits and safety of non-insulin medications used in the treatment of type 2 diabetes mellitus.
    Yandrapalli S; Jolly G; Horblitt A; Sanaani A; Aronow WS
    Postgrad Med; 2017 Nov; 129(8):811-821. PubMed ID: 28749197
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardiovascular outcomes with sodium-glucose cotransporter-2 inhibitors in patients with type II diabetes mellitus: A meta-analysis of placebo-controlled randomized trials.
    Saad M; Mahmoud AN; Elgendy IY; Abuzaid A; Barakat AF; Elgendy AY; Al-Ani M; Mentias A; Nairooz R; Bavry AA; Mukherjee D
    Int J Cardiol; 2017 Feb; 228():352-358. PubMed ID: 27866027
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Promising cardiovascular and blood pressure effects of the SGLT2 inhibitors: a new class of antidiabetic drugs.
    Chrysant SG
    Drugs Today (Barc); 2017 Mar; 53(3):191-202. PubMed ID: 28447076
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Effect of Sodium-Glucose Co-transporter-2 (SGLT-2) Inhibitors on Cardiometabolic Profile; Beyond the Hypoglycaemic Action.
    Lioudaki E; Androulakis ES; Whyte M; Stylianou KG; Daphnis EK; Ganotakis ES
    Cardiovasc Drugs Ther; 2017 Apr; 31(2):215-225. PubMed ID: 28444472
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The potential of sodium glucose cotransporter 2 (SGLT2) inhibitors to reduce cardiovascular risk in patients with type 2 diabetes (T2DM).
    Basile JN
    J Diabetes Complications; 2013; 27(3):280-6. PubMed ID: 23375850
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sodium-glucose co-transporter 2 inhibitors and the potential for cardiovascular risk reduction in patients with type 2 diabetes mellitus.
    Guthrie RM
    Postgrad Med; 2013 May; 125(3):21-32. PubMed ID: 23748504
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.